84.44
+11.03%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tempus AI
From its filings with the US Securities and Exchange Commission
Tempus AI is based in Chicago, Illinois and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker TEM. The SEC classifies its business as computer programming, data processing, etc.. In the fiscal year to 31 December 2025, it reported revenue of $1.27bn and a net loss of $245.0m. At that date it held total assets of $2.27bn and shareholders' equity of $491.3m.
We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare. Intelligent Diagnostics use AI, including generative and agentic AI, to make laboratory tests more accurate, tailored, and personal. We make tests intelligent by connecting laboratory results to a patient’s own clinical data, thereby personalizing the results. Our novel insight was realizing that all laboratory test results, genomic or otherwise, could be contextualized for a specific patient based upon that patient’s unique characteristics, and technology could therefore guide therapy selection and treatment decisions to allow each patient to progress on their own unique path. The drugs recommended, the clinical trials explored, the care pathways evaluated, and the adverse events considered—all have the potential to be refined and enhanced when test results are connected to a patient’s personal profile, enabling the right patient to be routed to the right therapy at the right time.
To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 14 Jun 2024
- Employees
- 3,800
- Website
- tempus.com ↗
- Head office
- 600 WEST CHICAGO AVENUE, CHICAGO, IL, 60654
- Incorporated in
- NV
- Classification
- Services-Computer Programming, Data Processing, Etc.
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Eric LefkofskyChief Executive Officer, Director$2,100
- Mr. James RogersChief Financial Officer$3.3m
- Mr. Ryan FukushimaChief Operating Officer$5.3m
- Mr. Erik PhelpsExecutive Vice President, Chief Administrative and Legal Officer, Assistant Secretary
- Mr. Andrew PolovinExecutive Vice President, General Counsel
- Mr. Peter BarrisIndependent Director
- Mr. Eric BelcherIndependent Director
- Dr. Jennifer DoudnaIndependent Director$75,000
- Mr. David EpsteinIndependent Director
- Dr. Wayne FrederickIndependent Director$75,000
- Mr. Robert GhenchevIndependent Director
- Dr. Scott GottliebIndependent Director$1.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company operates in Life Sciences Tools & Services sector with 3800 employees.
- Provides next generation diagnostics using genomics and AI applications.
- Offers AI platform Next for oncology and cardiology care gap identification.
Weaknesses
- IPO occurred on 2024-06-14, indicating recent market entry.
- Company is described as a technology company with unverified product claims.
- No specific financial metrics or market share data provided.
Opportunities
- Growth potential in personalized medicine through data analytics.
- Expansion of AI applications in healthcare diagnostics.
- Leveraging genomics and AI for broader disease area coverage.
Threats
- Untrusted source description may lead to inaccurate market positioning.
- Recent IPO could face volatility in stock performance.
- Competition in AI-driven healthcare diagnostics sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.